Table 1 Levels of YKL-40 and clinical characteristics of patients with ESCC
Characteristics | Case numbers | YKL-40(ng/ml) | |
|---|---|---|---|
Median(range) | p Valuea | ||
Age, years | |||
<60 | 81 | 71.56(6.95-340.70) | 0.001 |
≥60 | 69 | 122.36(21.32-502.05) | 0.001 |
Gender | |||
Male | 113 | 93.12(11.56-430.83) | 0.784 |
Female | 37 | 111.60(6.95-502.05) | 0.784 |
pT status | |||
pT1 | 5 | 93.12(21.32-264.66) | 0.975 |
pT2 | 21 | 104.27(30.26-430.83) | 0.975 |
pT3 | 65 | 91.55(6.95-421.34) | 0.975 |
pT4 | 45 | 101.50(14.64-351.66) | 0.975 |
pN status | |||
pN0 | 57 | 97.27(6.95-430.83) | 0.617 |
pN1 | 77 | 97.03(13.32-421.34) | 0.617 |
pM status | |||
pM0 | 107 | 93.24(6.95-430.83) | 0.198 |
pM1 | 32 | 108.82(14.64-419.22) | 0.198 |
pTNM status | |||
Stage I | 7 | 93.12(42.26-264.66) | 0.604 |
Stage II | 40 | 97.27(6.95-430.83) | 0.604 |
Stage III | 58 | 92.40(13.32-421.34) | 0.604 |
Stage IV | 32 | 108.82(14.64-419.22) | 0.604 |
Tumor grade | |||
Grade 1 | 24 | 108.39(24.95-234.89) | 0.579 |
Grade 2 | 57 | 94.21(11.56-376.09) | 0.579 |
Grade 3 | 41 | 71.02(6.95-419.22) | 0.579 |